Skip to main content
    T

    Tempest Therapeutics Inc (TPST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.64
    -0.00 (-0.03%)

    Market Cap: $11.51M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -50.34%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.32
    Range$-0.32 - $-0.32
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.35+8.6%
    60d ago$-0.35+8.6%
    30d ago$-0.35+8.6%
    7d ago$-0.35+8.6%
    Current$-0.32
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.95
    Range$-1.95 - $-1.95
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.95---
    Sep 26EST
    		-$-0.32---
    Jun 26
    Reported Aug 13
    		$-0.34$-0.30-13.33%Miss+83.6%
    Mar 26
    Reported May 14
    		$-0.50$-0.28-79.96%Miss+84.1%
    Dec 25
    Reported Mar 31
    		$-0.62$-0.62+0.00%Beat-100.0%
    Sep 25
    Reported Nov 5
    		$-0.79N/A+75.84%Beat+85.2%
    Jun 25
    Reported Aug 11
    		$-2.07$-3.23+35.91%Beat+62.1%
    Mar 25
    Reported May 13
    		$-3.16$-3.29+3.95%Beat+32.5%
    Dec 24
    Reported Mar 27
    		$-0.31$-0.24-26.53%Miss+18.4%
    Sep 24
    Reported Nov 12
    		$-5.33$-4.58-16.38%Miss+14.6%
    Jun 24
    Reported Aug 8
    		$-5.46$-5.33-2.44%Miss+22.2%
    Mar 24
    Reported May 9
    		$-4.68$-4.94+5.26%Beat+34.5%
    Dec 23
    Reported Mar 19
    		$-0.38$-0.39+2.56%Beat+39.7%
    Sep 23
    Reported Nov 8
    		$-6.24$-7.19+13.21%Beat+27.3%
    Jun 23
    Reported Aug 10
    		$-7.02$-7.54+6.90%Beat+31.6%
    Mar 23
    Reported May 10
    		$-7.15$-8.54+16.28%Beat-505.9%
    Dec 22
    Reported Mar 22
    		$-0.63$-0.76+17.11%Beat+92.1%
    Sep 22
    Reported Nov 8
    		$-8.58$-9.88+13.16%Beat+45.5%
    Jun 22
    Reported Aug 15
    		$-10.27$-12.00+14.42%Beat+25.0%
    Mar 22
    Reported May 13
    		$-1.18$-1.12-5.36%Miss+82.1%
    Dec 21
    Reported Mar 29
    		$-7.93N/A+50.53%Beat-35.6%
    Sep 21
    Reported Nov 10
    		$-15.73$-13.61-15.58%Miss-208.4%
    Jun 21
    Reported Aug 12
    		$-13.69$-11.37-20.40%Miss-63.0%
    Mar 21
    Reported May 13
    		$-6.60$-5.25-25.71%Miss+32.3%
    Dec 20
    Reported Mar 29
    		$-5.85$-5.15-13.59%Miss+55.2%
    Sep 20
    Reported Nov 9
    		$-5.10$-6.90+26.09%Beat+60.9%
    Jun 20
    Reported Aug 10
    		$-8.40$-8.20-2.44%Miss+24.3%
    Mar 20
    Reported May 8
    		$-9.75$-10.00+2.50%Beat+16.7%
    Dec 19
    Reported Mar 11
    		$-13.05$-12.18-7.14%Miss-6.1%
    Sep 19
    Reported Nov 13
    		$-13.05$-12.38-5.41%Miss-1551.9%
    Jun 19
    Reported Aug 12
    		$-11.10$-12.12+8.42%Beat-236.4%
    Mar 19
    Reported May 15
    		$-11.70$-10.55-10.90%Miss-271.4%
    Dec 18
    Reported Mar 29
    		$-12.30$-12.85+4.28%Beat+77.2%
    Sep 18
    Reported Nov 9
    		$-0.79N/A+80.49%Beat+98.6%
    Jun 18
    Reported Aug 9
    		$-3.30$-0.27-1122.22%Miss+97.1%
    Mar 18
    Reported May 3
    		$-3.15$-0.28-1025.00%Miss+96.3%
    Dec 17
    Reported Mar 15
    		$-54.00$-61.95+12.83%Beat+51.0%
    Sep 17
    Reported Nov 2
    		$-58.50$-89.78+34.84%Beat-
    Jun 17
    Reported Aug 3
    		$-114.75$-94.33-21.65%Miss-
    Mar 17
    Reported May 9
    		$-85.50$-95.96+10.90%Beat-
    Dec 16
    Reported Mar 2
    		$-110.25$-129.94+15.15%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.28EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-931.00%ROIC-616.88%
    Financial Health
    Debt/Equity-5.76xInterest CoverageN/A
    Current Ratio0.38xQuick Ratio0.38x
    Trading Statistics
    Beta-1.71Avg Volume5.87M
    52-Week High$11.1552-Week Low$0.64

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.74
    SMA 20$0.80
    SMA 50$0.93
    SMA 200$1.63
    EMA 10$0.73
    EMA 20$0.79
    EMA 50$0.90
    EMA 200$2.11

    MACD

    Line: -0.07Signal: -0.06Hist: -0.01

    ADX

    ADX: 17.6+DI: 19.7-DI: 23.8

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down100.0
    PSAR$1.13

    Bollinger Bands

    Upper Band$0.99
    Lower Band$0.62
    %B Position4637%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    35.0

    Momentum Oscillators

    Stoch %K2.3
    Stoch %D1.4
    Williams %R-93.6
    ROC (10d)-21.2%
    Momentum-0.17
    CCI (20d)-189.6
    MFI (14d)64.4

    Volatility Measures

    ATR (14d)$0.08(13.3%)
    StdDev (20d)0.09
    Hist Vol144.6%(High)

    Volume Flow

    VWAP$0.64
    OBV78.0M
    AD Line-35.5M
    CMF (20d)-0.128

    Volume Metrics

    Avg Vol (20d)832.4K
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.89

    Pivot Points

    R3$0.74
    R2$0.72
    R1$0.68
    Pivot Point$0.66
    S1$0.61
    S2$0.59
    S3$0.55

    Advanced Oscillators

    TSI-17.68
    Ultimate Osc24.7
    KST-214.55

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$486,000$0$0$0$0$0
    Cost of Revenue$0$0$65,000$0$0$0$243,000$0$0$0$85,000$0
    Gross Profit$0$0$-65,000$0$0$0$243,000$0$0$0$-85,000$0
    Operating Expenses$5.25M$27.72M$4.08M$3.60M$7.97M$10.94M$13.92M$10.55M$9.58M$7.97M$7.51M$6.59M
    R&D$1.82M$22.29M$538,000$570,000$3.87M$7.63M$10.74M$7.56M$5.84M$4.34M$4.18M$4.22M
    SG&A$3.43M$5.42M$3.54M$3.03M$4.09M$3.31M$3.18M$2.99M$3.75M$3.63M$3.33M$2.37M
    Operating Income$-5,250,000$-27,719,000$-4,076,000$-3,597,000$-7,966,000$-10,936,000$-13,919,000$-10,551,000$-9,582,000$-7,974,000$-7,514,000$-6,592,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$46,000$161,000$247,000$329,000$372,000$368,000$377,000$373,000
    Income Before Tax$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,870,000$-10,860,000$-13,813,000$-10,556,000$-9,570,000$-7,904,000$-7,488,000$-6,786,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,870,000$-10,860,000$-13,813,000$-10,556,000$-9,570,000$-7,904,000$-7,488,000$-6,786,000
    EBITDA$-5,184,000$-27,636,000$-3,956,000$-3,445,000$-7,757,000$-10,631,000$-13,517,000$-10,130,000$-9,043,000$-7,448,000$-7,026,000$-6,325,000
    EBIT$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,824,000$-10,699,000$-13,566,000$-10,227,000$-9,198,000$-7,536,000$-7,111,000$-6,413,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TPST

    News

    Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

    Tempest Therapeutics has appointed John W. Frederick to its board of directors, bringing extensive experience in financial strategy, capital markets...

    GlobeNewswire•10/14/26•Bullish

    Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

    Tempest Therapeutics, a clinical-stage biotechnology company, has appointed John W. Frederick to its board of directors. Frederick brings extensive experience in financial strategy, capital markets, corporate governance...

    GlobeNewswire•10/14/26•Bullish

    Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

    Tempest Therapeutics, a clinical-stage biotechnology company, announced the appointment of John W. Frederick to its board of directors. Mr. Frederick brings over three decades of executive leadership experience...

    GlobeNewswire•10/14/26•Bullish

    With $0 left to sell, Tempest Therapeutics (TPST) reports a warrant offering.

    Tempest Therapeutics (TPST) announced a fully sold $7.5 million warrant offering, comprising pre-funded warrants and common stock purchase warrants with a combined exercise price of $0.804. The offering also included...

    Stock Titan•10/14/26•Neutral

    Tempest Therapeutics Inc (TPST-Q) Stock Price and News

    This article provides stock information and recent news headlines for Tempest Therapeutics Inc. (TPST-Q), a clinical-stage oncology company. The news highlights various corporate activities including expansions...

    The Globe and Mail•10/7/26•Neutral

    TPST Valuation and Fair Value

    P/E
    -0.3x
    P/B
    -8.9x
    See GNG's fair value

    TPST Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -616.9%
    ROE
    -931.0%

    TPST Competitors

    CompanyTicker
    Intensity Therapeutics, Inc. Common stockINTS
    Alaunos Therapeutics IncTCRT
    Passage Bio IncPASG
    Kiora Pharmaceuticals IncKPRX
    In8bio IncINAB
    Ensysce Biosciences IncENSC
    Pluri Inc.PLUR
    Phio Pharmaceuticals CorpPHIO

    Sector: Healthcare

    TPST Bull Case vs Bear Case

    Bear case

    • TPST beat EPS estimates in 37.5% of its last 8 reported quarters.

    TPST Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -2.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.32
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TPST

    Does TPST pay dividends?

    Tempest Therapeutics Inc (TPST) does not currently pay a regular dividend.

    What is TPST's market cap?

    Tempest Therapeutics Inc (TPST) has a market capitalization of $11.51M with a current stock price of $0.64.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In